Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis

被引:123
|
作者
Jain, M
Ramirez, D
Seshadri, R
Cullina, JF
Powers, CA
Schulert, GS
Bar-Meir, M
Sullivan, CL
McColley, SA
Hauser, AR
机构
[1] Northwestern Univ, Dept Med, Chicago, IL 60611 USA
[2] Northwestern Univ, Dept Microbiol Immunol, Chicago, IL 60611 USA
[3] Northwestern Univ, Dept Pediat, Chicago, IL 60611 USA
[4] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA
[5] Northwestern Univ, Child Hlth Res Program, Childrens Mem Inst Educ & Res, Chicago, IL 60611 USA
[6] Childrens Mem Hosp, Div Infect Dis, Chicago, IL 60614 USA
[7] Childrens Mem Hosp, Div Pulm & Crit Care Med, Chicago, IL 60614 USA
关键词
D O I
10.1128/JCM.42.11.5229-5237.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Pseudomonas aeruginosa is a frequent cause of respiratory exacerbations in individuals with cystic fibrosis. An important virulence determinant of this pathogen is its type III protein secretion system. In this study, the type III secretion properties of 435 P. aeruginosa respiratory isolates from 56 chronically infected individuals with cystic fibrosis were investigated. Although it had been previously reported that 75 to 90% of P. aeruginosa isolates from patients with hospital-acquired pneumonia secreted type III proteins, only 12% of isolates from cystic fibrosis patients did so, with nearly all of these isolates secreting ExoS and ExoT but not ExoU. Despite the low overall prevalence of type III protein-secreting isolates, at least one secreting isolate was cultured from one-third of cystic fibrosis patients. Interestingly, the fraction of cystic fibrosis patient isolates capable of secreting type III proteins decreased with duration of infection. Although 90% of isolates from the environment, the presumed reservoir for the majority of P. aeruginosa strains that infect patients with cystic fibrosis, secreted type III proteins, only 49% of isolates from newly infected children, 18% of isolates from chronically infected children, and 4% of isolates from chronically infected adults with cystic fibrosis secreted these proteins. Within individual patients, isolates of clonal origin differed in their secretion phenotypes, indicating that as strains persisted in cystic fibrosis patient airways, their type III protein secretion properties changed. Together, these findings indicate that following infection of cystic fibrosis patient airways, P. aeruginosa strains gradually change from a type III protein secretion-positive phenotype to a secretion-negative phenotype.
引用
收藏
页码:5229 / 5237
页数:9
相关论文
共 50 条
  • [1] The type III secretion system in Pseudomonas aeruginosa during chronic infection and adaptation to the cystic fibrosis lung
    Schmoldt, S
    Hogardt, M
    Adler, K
    Heesemann, J
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2004, 294 : 233 - 233
  • [2] Evolution of Pseudomonas aeruginosa type III secretion in cystic fibrosis: a paradigm of chronic infection
    Jain, Manu
    Bar-Meir, Maskit
    Mccolley, Susanna
    Cullina, Joanne
    Potter, Eileen
    Powers, Cathy
    Prickett, Michelle
    Seshadri, Roopa
    Jovanovic, Borko
    Petrocheilou, Argyri
    King, John D.
    Hauser, Alan R.
    TRANSLATIONAL RESEARCH, 2008, 152 (06) : 257 - 264
  • [3] Pseudomonas aeruginosa type III secretion and lung function decline in cystic fibrosis
    Jain, M.
    Bar-Meir, M.
    King, J.
    Cullina, J.
    Potter, E.
    Powers, C.
    Seshadri, R.
    Yogev, R.
    McColley, S. A.
    PEDIATRIC PULMONOLOGY, 2007, : 316 - 317
  • [4] Why is Pseudomonas aeruginosa a common cause of infection in individuals with cystic fibrosis?
    Gross, Jeremy
    Welch, Martin
    FUTURE MICROBIOLOGY, 2013, 8 (06) : 697 - 699
  • [5] Pseudomonas aeruginosa infection and cystic fibrosis
    Kato, K
    Takayama, T
    LANCET, 2002, 359 (9302): : 262 - 262
  • [6] Pseudomonas aeruginosa infection in cystic fibrosis
    Hoiby, Niels
    APMIS, 2007, 115 (05) : 621 - 628
  • [7] Pseudomonas aeruginosa In Vitro Phenotypes Distinguish Cystic Fibrosis Infection Stages and Outcomes
    Mayer-Hamblett, Nicole
    Rosenfeld, Margaret
    Gibson, Ronald L.
    Ramsey, Bonnie W.
    Kulasekara, Hemantha D.
    Retsch-Bogart, George Z.
    Morgane, Wayne
    Wolter, Daniel J.
    Pope, Christopher E.
    Houston, Laura S.
    Kulasekara, Bridget R.
    Khan, Umer
    Burns, Jane L.
    Miller, Samuel I.
    Hoffman, Lucas R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 190 (03) : 289 - 297
  • [8] EARLY EVOLUTION OF PSEUDOMONAS AERUGINOSA DURING CYSTIC FIBROSIS INFECTION
    Jorth, P.
    Rezayat, A.
    Hisert, K. B.
    Garudathri, J.
    Khan, U.
    Hamblett, N. M.
    Singh, P.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 304 - 304
  • [9] Type III apparatus of Pseudomonas aeruginosa as a tool to diagnose pulmonary infection in cystic fibrosis patients
    Cruz, Aline C.
    Neves, Bianca C.
    Higa, Laurinda Y. S.
    Folescu, Tania
    Marques, Elizabeth A.
    Milagres, Lucimar G.
    APMIS, 2012, 120 (08) : 622 - 627
  • [10] A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates
    Wareham, David W.
    Curtis, Michael A.
    INTERNATIONAL JOURNAL OF MEDICAL MICROBIOLOGY, 2007, 297 (04) : 227 - 234